Home Stimulation for Brain-Asphyxiated Infants
Hypoxia, Brain, Hypoxia-Ischemia, Brain
About this trial
This is an interventional treatment trial for Hypoxia, Brain focused on measuring Neonatal brain injury, Brain Hypoxia, Cerebral Hypoxia, Brain Hypoxia-Ischemia, Brain Ischemia-Hypoxia, Cerebral Hypoxia-Ischemia, Cerebral Ischemia-Hypoxia, Environmental enrichment, Cognitive/sensorimotor stimulation, Parent-infant interactions, Prenatal hypoxia
Eligibility Criteria
Inclusion Criteria All of the following criteria must be met: Gestation age (GA) at birth >= 28 weeks Discharged to home care with parent or other guardian who has legal authority to give informed consent Greater than 10th percentile for GA at birth using the scales according to Lubchenco, Hansman, and Boyd from Pediatrics 1966 volume 37 and Battaglia and Lubchenco in the Journal of Pediatrics 1967 volume 71 Jewelry in pierced body parts can be removed Mothers > 17 years old Recruited within 60 days of EDC (estimated date of conception) Two or more of the following must be met: Intrapartum distress as determined by placental abruption, thick meconium staining of amniotic fluid, sustained fetal bradycardia of heart rate < 100 beats/min, or late or absent heart rate variability Profound metabolic or mixed academia as determined by umbilical artery pH < 7.0, base deficit of > 10 mEq/L or pH < 7.1 and base excess greater than 14 mmol/L within 72 hours of birth, Apgar score < 5 at 5 minutes or beyond, or need for positive pressure ventilation resuscitation for > 1 min after birth Neonatal neurological manifestations such as seizures during hospital stay, lethargy, hypotonia or hypertonia, stupor, flaccidity, or decerebration Multiple organ system dysfunction Abnormal EEG, CT scan, or MRI consistent with hypoxic or ischemic brain insult Exclusion Criteria: Infants of substance abusing mothers (ISAM) Intrauterine growth retardation (IUGR) Infants requiring extracorporeal membrane oxygenation (ECMO) in the neonatal period Hearing or visual impairment Congenital cyanotic heart disease with cyanosis and requiring PGE infusion. Children with minimum cardiac structural anomalies (e.g., PDA or VSD or peripheral pulmonary stenosis) will not be excluded from the study. Congenital abnormalities of the central nervous system such as congenital hydrocephalus Grade IV intraventicular hemorrhage requiring ventriculo-peritoneal shunt (VP shunt) Trisomy 13, 18, or 21, or Fragile X Metabolic encephalopathy from inborn errors of metabolism (e.g. PKU, OTC) Metal or wire mesh implants, pacemaker implants, cochlear implants, orthopedic surgical wires or implants Status epilepticus Ventilator dependent at discharge Infectious meningitis Encephalitis with radiological evidence of severe cortical or severe hemispheric destruction Silastic catheters, broviacs, or Hickman port home TPA Infants who may not be available for the duration of the study Any infant who in the opinion of investigator has no potential to benefit from the intervention (e.g., children with prenatal herpes meningitis, severe cortical destruction, mother does not follow up with the intervention or with the follow-up appointments)
Sites / Locations
- University of California at Los Angeles